SCHEMBL1630619

SCHEMBL1630619

O=CN(Cc1cccnc1)c1cc(F)c(-c2cn[nH]c2)nc1NCCc1cccc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.42
CSNK2A2 P19784 2/20 0.37
CSNK2A1 P68400 2/20 0.37
PKM P14618 1/20 0.35
ROCK2 O75116 9/20 0.35
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
CCNT1 O60563 1/20 0.34
CDC7 O00311 1/20 0.34
PIM1 P11309 1/20 0.34
CDK2 P24941 1/20 0.34
GSK3B P49841 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
CYP3A4 P08684 1/20 0.33
PTAFR P25105 1/20 0.33
ROCK1 Q13464 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1631686 0.92 GBA1 (0.43) GBA1CSNK2A2CSNK2A1PKMROCK2
SCHEMBL1632637 0.88 GBA1 (0.43) GBA1CSNK2A2CSNK2A1PKMROCK2
SCHEMBL1630998 0.88 KDM4E (0.43) GBA1CSNK2A2CSNK2A1ROCK2ROCK1
SCHEMBL4185997 0.87 GBA1 (0.46) GBA1CSNK2A2CSNK2A1PKMROCK2
SCHEMBL1630883 0.87 ROCK2 (0.35) GBA1CSNK2A2CSNK2A1ROCK2ROCK1
SCHEMBL1630599 0.84 KDM4E (0.33) PKMROCK2PIM1CDK2CYP3A4
SCHEMBL1632561 0.84 GBA1 (0.41) GBA1CSNK2A2CSNK2A1PKMOPRM1
SCHEMBL1630053 0.84 ROCK2 (0.37) GBA1CSNK2A2CSNK2A1ROCK2ROCK1
SCHEMBL1630722 0.80 GBA1 (0.49) GBA1CSNK2A2CSNK2A1PKMOPRM1
SCHEMBL1631250 0.80 GBA1 (0.51) GBA1CSNK2A2CSNK2A1PKMOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US claimed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 GBA1 4031/4885CSNK2A2 595/4885CSNK2A1 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.